Your browser doesn't support javascript.
MIF is a Common Genetic Determinant of COVID-19 Symptomatic Infection and Severity.
Shin, Junghee J; Fan, Wei; Par-Young, Jennefer; Piecychna, Marta; Leng, Lin; Israni-Winger, Kavita; Qing, Hua; Gu, Jianlei; Zhao, Hongyu; Schulz, Wade L; Unlu, Serhan; Kuster, John; Young, Grant; Liu, Jian; Ko, Albert I; Baeza Garcia, Alvaro; Sauler, Maor; Wisnewski, Adam V; Young, Lawrence; Orduña, Antonio; Wang, Andrew; Klementina, Ocskay; Garcia, Antonio Blesa; Hegyi, Peter; Armstrong, Michelle E; Mitchell, Patrick; Ordiz, David Bernardo; Garami, András; Kang, Insoo; Bucala, Richard.
  • Shin JJ; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Fan W; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Par-Young J; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Piecychna M; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Leng L; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Israni-Winger K; Department of Medicine, Department of Immunobiology, New Haven, CT, USA.
  • Qing H; Department of Medicine, Department of Immunobiology, New Haven, CT, USA.
  • Gu J; Department of Pathology, New Haven, CT, USA.
  • Zhao H; Department of Pathology, New Haven, CT, USA.
  • Schulz WL; Department of Medicine, Department of Immunobiology, New Haven, CT, USA.
  • Unlu S; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Kuster J; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Young G; Cardiology, New Haven, CT, USA.
  • Liu J; Department of Pathology, New Haven, CT, USA.
  • Ko AI; Department of Pathology, New Haven, CT, USA.
  • Baeza Garcia A; Inserm 1231 Lipids, Nutrition Cancer, Dijon, France.
  • Sauler M; Pulmonary, Critical Care, and Sleep Medicine, New Haven, CT, USA.
  • Wisnewski AV; Department of Laboratory Medicine, New Haven, CT, USA.
  • Young L; Cardiology, New Haven, CT, USA.
  • Orduña A; Microbiology Service. Hospital Clínico Universtario. Valladolid. Spain.
  • Wang A; Sections of Rheumatology, Allergy and Immunology, New Haven, CT, USA.
  • Klementina O; Department of Medicine, Department of Immunobiology, New Haven, CT, USA.
  • Garcia AB; Universidad de Valladolid, Valladolid, Spain; University of Pécs, Pécs, Hungary. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Hegyi P; Centre for Translational Medicine, Semmelweis University, Budapest Hungary.
  • Armstrong ME; Mucosal Immunology Lab. Unidad de Excelencia Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid-CSIC. Valladolid. Spain.
  • Mitchell P; Universidad de Valladolid, Valladolid, Spain; University of Pécs, Pécs, Hungary. Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Ordiz DB; Centre for Translational Medicine, Semmelweis University, Budapest Hungary.
  • Garami A; Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Kang I; Trinity College Dublin, Dublin, Ireland.
  • Bucala R; Trinity College Dublin, Dublin, Ireland.
QJM ; 2022 Oct 12.
Article in English | MEDLINE | ID: covidwho-2281184
ABSTRACT

BACKGROUND:

Genetic predisposition to COVID-19 may contribute to its morbidity and mortality. Because cytokines play an important role in multiple phases of infection, we examined whether commonly occurring, functional polymorphisms in macrophage migration inhibitory factor (MIF) are associated with COVID-19 infection or disease severity.

AIM:

To determine associations of common functional polymorphisms in MIF with symptomatic COVID-19 or its severity.

METHODS:

This retrospective case control study utilized 1171 patients with COVID-19 from three tertiary medical centers in the United States, Hungary, and Spain, together with a group of 637 pre-pandemic, healthy control subjects. Functional MIF promoter alleles (-794 CATT5-8, rs5844572), serum MIF and soluble MIF receptor levels, and available clinical characteristics were measured and correlated with COVID-19 diagnosis and hospitalization. Experimental mice genetically engineered to express human high- or low-expression MIF alleles were studied for response to coronavirus infection.

RESULTS:

In patients with COVID-19, there was a lower frequency of the high-expression MIF CATT7 allele when compared to healthy controls (11% vs. 19%, OR 0.54 [0.41, 0.72], p < 0.0001). Among inpatients with COVID-19 (n = 805), there was a higher frequency of the MIF CATT7 allele compared to outpatients (n = 187) (12% vs. 5%, OR 2.87 [1.42, 5.78], p = 0.002). Inpatients presented with higher serum MIF levels when compared to outpatients or uninfected healthy controls (87 ng/ml vs. 35 ng/ml vs. 29 ng/ml, p < 0.001, respectively). Among inpatients, circulating MIF concentrations correlated with admission ferritin (r = 0.19, p = 0.01) and maximum CRP (r = 0.16, p = 0.03) levels. Mice with a human high-expression MIF allele showed more severe disease than those with a low-expression MIF allele.

CONCLUSIONS:

In this multinational retrospective study of 1171 subjects with COVID-19, the commonly occurring -794 CATT7  MIF allele is associated with reduced susceptibility to symptomatic SARS-CoV-2 infection but increased disease progression as assessed by hospitalization. These findings affirm the importance of host genetics in different stages of COVID-19 infection.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Qjmed

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Observational study / Prognostic study Language: English Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Qjmed